Drug Profile
Research programme: echovirus therapeutics - Viralytics
Alternative Names: ECHO-1; EVATAKLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ViroTarg
- Developer Viralytics
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastric cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastric-cancer in Australia (Intraperitoneal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in Australia (Intraperitoneal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in Australia (Intratumoural)